Whereas this selective targeting of FA-deficient HSPCs by PLK1 inhibition may be beneficial in the setting of sporadic AML, it suggests that PLK1 inhibitors, much like DNA-damaging agents (1), may induce high toxicities in patients with germline FA mutations. The gene discussed is FANCA; the disease is acute myeloid leukemia.